Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Inclusion Criteria:

Histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC)
Disease must have progressed after at least 2 prior chemotherapy regimens for NSCLC
Patients must have measurable or nonmeasurable disease
Absolute neutrophil count at least 1,500/mm^3
Platelet count at least 100,000/mm^3
Bilirubin no greater than 1.5 times upper limit of normal (ULN)
AST and ALT no greater than 3 times ULN (5 times ULN in patients with liver disease)
Creatinine less than 1.5 times ULN or calculated creatinine clearance greater than 50 mL/min
More than 3 weeks since prior chemotherapy, radiotherapy, immunotherapy or other investigational drug use
Recovered from all prior therapy
Fertile patients must use effective contraception
Age >= 18
ECOG performance status of 0-1

Exclusion Criteria:

Prior primary or metastatic brain or meningeal tumors unless clinically and radiographically stable and off therapy for at least 2 months
Active second malignancy
Clinically evident congestive heart failure, serious cardiac arrhythmias, or symptoms of coronary heart disease
Prior radiotherapy to the only site of measurable or evaluable disease unless there is evidence of disease progression in that site
Prior exposure to a ras pathway inhibitor (e.g., farnesyl transferase inhibitor)

Concurrent medications known to be metabolized by the liver with a narrow therapeutic index, including the following:

Ketoconazole
Itraconazole
Quinidine
Digoxin
Cyclosporine
Ritonavir
Grapefruit products
Carbamazepine
Phenytoin
Phenobarbital
Pregnant or nursing
Clinically serious active infection
Medical conditions, substance abuse or psychological/social situation that would preclude study participation